255 results about "Combination drug" patented technology

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention discloses a graph attention enhancing drug recommendation model algorithm fused with clinical signs, which comprises the following steps: representing a patient according to complete medical information, and capturing a patient health condition change rule contained in EHRs through a gating neural network; in the patient characterization process, medicine combination knowledge and DDI knowledge are effectively utilized through GNN and are fused into the patient characterization process; the method comprises the following steps: reading patient medication information which is integrated with DDI knowledge and has patient similarity and historical diagnosis and treatment records through a two-stage attention module, and converting drug recommendation into a multi-label prediction task; the method has the advantages that the related performance of the model in combined drug prediction is superior to that of a comparison model, the relatively good Jaccard index, F1-Score, PR-AUC and DDI rate are obtained, and a new thought is provided for clinical decision making and drug recommendation based on the graph neural network.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

The invention provides application of sulfasalazine and a combined drug thereof in drug-resistant head and neck malignant tumors, which comprises the following steps: when the sulfasalazine is independently used, the sulfasalazine has a treatment effect on the drug-resistant head and neck malignant tumors and can delay the growth of the drug-resistant head and neck malignant tumors; combined use of sulfasalazine and chemotherapeutic drugs has a synergistic effect, and the sulfasalazine can be used for treating drug-resistant head and neck malignant tumors. The technical problem to be solved by the invention is to explore the drug activity of sulfasalazine in the treatment of drug-resistant head and neck malignant tumors and solve the limitation of drug resistance to treatment in the drug treatment process.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and more particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of diabetes. The TCM composition of this invention includes *Sedum sarmentosum*, seaweed, oyster shell, hawthorn, *Siegesbeckia orientalis*, *Schisandra chinensis*, and *Polygonum cuspidatum*. This invention has found that this composition can significantly reduce blood glucose levels in type 2 diabetic rats and increase serum insulin levels and insulin sensitivity index in rats. Moreover, the compound combination drug for treating diabetes is an existing TCM preparation, safe to use, and its preparation method is simple, rapid, efficient, and easy to operate. The prepared mixtures, tablets, capsules, and micro-pills are easy to carry and convenient to take.

The invention provides a composition and an application thereof in tumor anti-lactylation, and belongs to the technical field of biological medicines. The corilagin and the baicalein are combined to be applied to tumor treatment, a stronger glycolysis inhibition effect can be shown, a main energy supply way of tumor cells can be more effectively cut off, and rapid proliferation and growth of the tumor cells are restrained. The combination of corilagin and baicalein provided by the invention provides a new potential molecular combination drug for lung cancer treatment, provides a new treatment choice for patients, develops a new idea for the field of tumor treatment, proves the potential of a natural compound combination in tumor anti-lactic acid treatment, and has a wide application prospect. Reference and reference are provided for subsequent research and development of more tumor treatment drugs and strategies based on natural products.

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and a KRas G12C inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.

The invention relates to the technical field of biology, in particular to application of lonidamine combined with apigenin to treatment of colorectal cancer. The invention provides a novel pharmaceutical composition for treating colorectal cancer. LND and AP form the pharmaceutical composition according to different molar concentrations or different weight ratios, the anti-tumor activity of the pharmaceutical composition is respectively tested on a colon cancer cell line MC38 culture and a tumor-bearing mouse, and results prove that compared with the effect of a single drug, the combined drug obviously improves the activity of anti-tumor cells in vitro or in vivo.

The invention provides a combined medicine recommendation method based on multi-modal alignment. A core module of the recommendation method comprises a cloth perception multi-modal medicine alignment module, a time sequence multi-view patient aggregation module and a combined medicine recommendation module. According to the recommendation method, electronic health records EHRs serve as a data source, multi-modal information matched with physical signs of a patient and medicine application characteristics is obtained, effective alignment and fusion are conducted on the multi-modal information through the core module, and suggestion data matched with the multi-modal information and composed of multiple medicines are generated. A DDI loss function and a dynamic weighting strategy are introduced to process conflicts among different drugs in the generated suggestion data so as to output safe suggestion data, and it is avoided that conflicting drugs are recommended in the suggestion data; according to the method, personalized, high-safety, scientific and reasonable drug combination suggestions can be provided.

The present invention discloses the application of Ganoderma lucidum lanostane triterpenoids in the preparation of CYP metabolic enzyme inhibitors, belonging to the technical field of pharmaceuticals. The structural formula of this compound is as follows: #imgabs0# The present invention also provides the application of lanostane triterpenoids in the preparation of CYP metabolic enzyme inhibitors, and evaluates their inhibitory effects on various subtypes of CYP enzymes and the intervention of drug metabolism. The lanostane triterpenoids provided by the present invention can effectively inhibit the activities of various CYP metabolic enzymes, and can be used as combination drugs in inhibiting the hepatic metabolism of clinical drugs, providing a reference for the clinical use of Ganoderma lucidum.

The invention relates to the field of biological medicine, and discloses an anti-tumor combined drug, the anti-tumor combined drug comprises a two-factor oncolytic virus and an HER2 CAR-T cell, the two-factor oncolytic virus is an OV-OX40L / IL12 oncolytic virus capable of simultaneously expressing OV-OX40L and IL12, the HER2 CAR-T cell is a cell specially targeting an HER2 antigen, and the CAR structure contained in the HER2 CAR-T cell comprises Anti-HER2 scfv, CD8hinge, CD8TM, CD28-4-1BB, CD3zeta, IRES and EGFP. The CAR-T therapy and the oncolytic virus therapy are combined, the advantages of the CAR-T therapy and the oncolytic virus therapy are mutually promoted, the infiltration and the activity of the CAR-T cells in solid tumors are enhanced by the two-factor oncolytic viruses, and meanwhile, the oncolytic virus-mediated oncolytic property can be improved by the CAR-T cells.

The invention discloses a TCR capable of recognizing MAGE-A3 antigen oligopeptide, a compound, a nucleic acid molecule, an expression vector, a cell, a combined drug and application of the TCR, the TCR comprises one or two of a TCR alpha chain and a TCR beta chain, a TCR alpha chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 5, a TCR beta chain variable region comprises an amino acid sequence as shown in SEQ ID NO: 9, a CDR3 amino acid sequence of the TCR alpha chain variable region is as shown in SEQ ID NO: 4, and the CDR3 amino acid sequence of the TCR beta chain variable region is as shown in SEQ ID NO: 5. The CDR3 amino acid sequence of the TCR beta chain variable region is as shown in SEQ ID NO: 8, the TCR alpha chain variable region and the SEQ ID NO: 5 have at least 80% of the same amino acid sequence, and the TCR beta chain variable region and the SEQ ID NO: 9 have at least 80% of the same amino acid sequence.

The present invention belongs to the field of biomedicine technology, and specifically relates to a combination drug combination and application for inhibiting the proliferation of NPM1 mutant leukemia cells. The combination drug combination includes RAS selective lethal molecule 3 and sulfonamide antibiotics; and anti-tumor small molecule drugs. The sulfonamide antibiotics include sulfasalazine; the anti-tumor small molecule drugs are selected from one or more of cytarabine, daunorubicin and venetoclax. The present invention also provides the application of the pharmaceutical composition in the combination drug combination in the preparation of an NPM1 mutant leukemia ferroptosis effect evaluation reagent.

The present disclosure provides a combination comprising an antibody that specifically binds to C5 and a C5 iRNA, which is a glycoconjugate containing a ligand with a terminal N-acetylgalactosamine (GalNAc) residue and / or N-acetylglucosamine (GlcNAc) residue. A method for reducing degradation of glycoconjugate RNA by the beta-hexosaminidase enzyme is also provided. The present disclosure also includes a method for treating or preventing a C5-related disease or disorder by administering one or more doses of an anti-C5 antibody or antigen-binding fragment thereof in combination with one or more doses of a C5 iRNA; preferably, the anti-C5 antibody or fragment and the C5 iRNA are in a combination. The present disclosure also includes a dosing regimen for treating a C5-related disease or disorder with a combination of an anti-C5 antibody and a C5 iRNA in either a treatment-naive subject or a subject switching from a previous C5 inhibitor therapy.

The invention provides a drug combination composition for treating or / and improving attention impairment and application thereof, and relates to the technical field of biological medicine, the drug combination composition comprises isorhynchophylline and ginsenoside Rg1, and the isorhynchophylline and ginsenoside Rg1 are creatively combined to be used as a drug for treating or / and improving attention impairment. Researches show that the combination of isorhynchophylline and ginsenoside Rg1 has a more significant effect of treating or / and improving attention impairment than single isorhynchophylline or ginsenoside Rg1, provides a new strategy and idea for treating or / and improving attention impairment, and has very significant significance.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The invention discloses a composition, a medicine with the composition and application of the composition. The composition comprises radix aconiti carmichaeli and other qi promoting components, a blood stasis dispersing component; components for warming spleen and stomach, dispelling cold, reviving yang and tonifying spleen Liquorice; a blood generating and activating component; a wind-cold dispersing component; a kidney reinforcing component; the composition disclosed by the invention has a good antiviral effect, and can assist qi and blood generation so as to transform cold-dampness, so that antiviral effect is realized, and meanwhile, the body function is improved.

This invention provides the application of a composition in the preparation of drugs for osteoarthritis, belonging to the field of arthritis technology. The composition comprises tofu glycosides, N-acetylcysteine, seaweed peptides, and PDGF. The combination of these drugs significantly enhances the chondrogenic differentiation and migration capacity of chondrocyte stem cells under inflammatory conditions. Furthermore, in an SD rat knee osteoarthritis model, chondrocyte stem cells treated with the enhanced culture medium reduced the Wakitani histological score from 8.83 to 2.17±0.98, demonstrating a superior repair effect compared to traditional methods. Therefore, this invention provides a foundation for the efficient treatment of osteoarthritis.

This invention discloses a trimethyl chitosan-hyaluronic acid-FMNL2 siRNA nanomedicine and its applications. The siRNA molecule consists of a sense strand and an antisense strand, which are anti-complementary to form a double-stranded RNA structure. Each of the sense and antisense strands independently contains two pendant deoxythymidines at its 3' end. The nanomedicine uses trimethyl chitosan as its core framework, efficiently encapsulating the siRNA molecule through electrostatic interactions, and then modifying hyaluronic acid through electrostatic interactions to form core-shell structured nanoparticles. This invention forms a complete technology chain from target validation, siRNA sequence design, nanodelivery system construction, in vivo and in vitro efficacy verification to the development of combination drug strategies. It also provides quantifiable efficacy evaluation biomarkers, offering a clear basis for clinical patient screening and efficacy monitoring.

The present invention discloses the application of the combined drug of mecobalamin (MeCbl) and Shuilinjia (SC) in the treatment of non-alcoholic steatohepatitis (NASH). The present invention firstly proposes that oral MeCbl can effectively intervene in and treat the progression of NASH disease, and firstly proposes that the combined drug of oral MeCbl and SC can synergistically enhance the treatment of NASH, as well as liver injury, inflammation, liver fibrosis and hepatic lipid deposition on the basis of monomeric drugs. The MeCbl / SC composition in the present invention has a potent effect on the treatment of NASH, provides a new therapeutic drug for such refractory liver diseases clinically, while reducing the single-drug use dose of SC, and reducing the incidence of adverse reactions and treatment costs of patients. The pharmacokinetics and safety data of the drug molecules involved in the present invention are relatively detailed, and the development of new indications can quickly enter clinical evaluation, saving development costs while shortening the R & D cycle.

The invention belongs to the technical field of medicine preparation, and particularly relates to a nitraria tangutorum composite medicine, which is prepared from the following raw materials in parts by weight: 10 to 30 parts of nitraria tangutorum, 0 to 30 parts of herba elsholtziae, 0 to 20 parts of pink reineckea herb and 0 to 20 parts of stevia rebaudiana. The preparation method comprises the following steps: respectively cleaning and drying the sophora davidii, the elsholtzia, the pink reineckea herb and the stevia rebaudiana according to the proportion, crushing into powder, and uniformly mixing to obtain raw material powder of the sophora davidii combined medicine. The raw material powder can be further prepared into dosage forms such as granules, tablets, capsules or oral liquid. The nitraria tangutorum var. Davidii combined medicine is applied to treatment of pneumonia including bacterial pneumonia, viral pneumonia and the like.

The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.

The invention discloses a kit for predicting the treatment effect of a combined drug composition for cervical cancer, which predicts the treatment effect of a'VEGFR inhibitor + PD-1 monoclonal antibody 'combined scheme by detecting serum arginine or SLC6A14 expression quantity in cervical cancer tissues, can help patients to select the treatment scheme in a more targeted manner, can improve the effectiveness of drug use, and has the advantages of simple operation, low cost and high efficiency. And poor prognosis or treatment opportunity delay caused by selection of treatment schemes is avoided, and the method has a good application prospect.

The present application relates to the technical field of biological pharmacy, in particular to a combined drug for treating colitis and application thereof, wherein the volume ratio of Coptis exosome and Salmonella outer membrane vesicle in the combined drug is 1-2:1-3; the concentration of the Coptis exosome and the Salmonella outer membrane vesicle is 9-11 mg / mL. The present application overcomes the limitation of single treatment strategy by innovatively combining the Coptis exosome and the Salmonella outer membrane vesicle, significantly improves the treatment effect, and avoids the side effects of existing drugs. The present application has lower treatment cost, is safer and has no drug resistance problem, and can provide a more effective, safe and economical treatment method for inflammatory diseases such as colitis.

Use of a quinazoline compound and a third-generation epidermal growth factor receptor (EGFR) inhibitor in a combined drug for treating non-small cell lung cancer. The quinazoline compound comprises at least one of a quinazoline derivative represented by formula (I), a salt thereof, a solvate thereof, a hydrate thereof, and a polymorph thereof.

The invention relates to a folic acid conjugate as well as a preparation method and application thereof. Specifically, the invention discloses a novel folic acid conjugate and a drug combination strategy thereof, and also provides a preparation method of the conjugate and an application of the conjugate in tumor treatment. The conjugate provided by the invention has folate receptor expression dependence, can efficiently inhibit ovarian cancer cell proliferation, and shows a good action effect when being combined with a DNA (Deoxyribose Nucleic Acid) damaging agent.

The invention discloses a combined medicine for preventing and treating chronic cervicitis and a preparation method thereof. The combined medicine comprises a scavenger I and a scavenger II, according to the combined medicine and the preparation method provided by the invention, comprehensive treatment is carried out by combining a mature therapy and an elimination therapy which are special for Uighur medicine, the vagina environment is changed, the local immune function is improved, and a treatment mode which is definite in curative effect, safe and low in price is provided for chronic cervicitis.

The disclosure, in one aspect, relates to methods for treating cancer in a subject, the methods including at least the steps of administering at least one drug from each of at least two classes selected from an inhibitor of poly-ADP ribose polymerase (PARP inhibitor), an inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs inhibitor), an inhibitor of wild-type isocitrate dehydrogenase (IDH inhibitor), an inhibitor of histone acetyltransferase (HAT inhibitor), an inhibitor of histone deacetylase (HDAC inhibitor), an inhibitor of DNA polymerase Θ (POLΘ inhibitor), an inhibitor of platelet-derived growth factor receptor (PDGFR inhibitor), and a DNA alkylating agent to the subject. In any of these aspects, the disclosed method allows for administering lower doses of the drugs in combination compared to administration as single drugs while preventing the recurrence of the cancer, preventing drug resistance of the cancer, and reducing side effects associated with cancer treatment.

The invention discloses an application of a GABAA alpha 6 receptor knockout substance and a combined drug thereof in preparation of a bladder cancer treatment product. The invention provides an application of a substance for knocking out a GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a tumor treatment product. The invention also provides application of a substance for knocking out the GABAA alpha 6 receptor gene and a macrophage inhibition drug in preparation of a product for inhibiting tumor progression. By knocking out the GABAA alpha6 receptor gene, the regulation effect of the GABAA alpha6 receptor gene on CD8 + T cell functions is researched, the application value of the GABAA alpha6 receptor gene in bladder cancer treatment is verified, and a new strategy is provided for clinical treatment.